Literature DB >> 16198066

Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?

Giuseppe Sanguineti1, Matthew L Cavey, Eugene J Endres, Gunn G Brandon, John E Bayouth.   

Abstract

PURPOSE: To assess whether a 4-field box technique (4FBT), along with its technical refinements, is an adequate approach in terms of rectal sparing and target coverage for patients with localized prostate cancer undergoing whole-pelvic radiotherapy followed by a prostate boost and whether or not intensity-modulated radiotherapy (IMRT) is needed. METHODS AND MATERIALS: For 8 patients, 31 plans were generated, each of them differing in one or more features, including prescription (dose/volume) and/or technical factors. For the latter, several "solutions" to try to reduce the amount of irradiated rectal volume were addressed, including modifications of the 4FBT and the use of sequential IMRT. We constructed a database with 248 plans that were tested for their ability to meet a series of rectal dose-volume constraints at V50, V60, V65, V70, V75, and V75.6. Multivariate logistic regression was used to identify factors independently associated with the end point. Successful solutions were also compared in terms of coverage of both pelvic node and prostate planning target volume (PTV) by isodose 95%.
RESULTS: At multivariate logistic regression, both rectal blocking and IMRT were independent predictors of the probability of meeting rectal dose-volume constraints during the pelvic and boost phases of treatment with close relative risks. However, on average, partial rectal blocking on lateral fields of 4FBT during whole-pelvic radiotherapy resulted in about 3% of pelvic node PTV being outside isodose 95%; only 2 of 8 patients had the pelvic nodal PTV covered similarly to what was achieved by whole-pelvis IMRT. Conversely, blocking the rectum during the last 3 fractions of the conformal boost showed a dosimetric coverage of prostate PTV similar to that achieved by IMRT boost. Interestingly, patient anatomic configuration was the strongest predictor of rectal sparing. Finally, the size of prostate margins to generate PTV was also independently associated with the probability of meeting rectal dose-volume constraints.
CONCLUSION: In the dose range of 70-76 Gy to the prostate, IMRT and standard techniques are equally effective in meeting rectal dose-volume constraints. However, whole-pelvis IMRT might be preferable to standard techniques for its slightly superior PTV coverage.

Entities:  

Mesh:

Year:  2005        PMID: 16198066     DOI: 10.1016/j.ijrobp.2005.06.026

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Prostate image-guided radiotherapy by megavolt cone-beam CT.

Authors:  Sergio Zucca; Barbara Carau; Ignazio Solla; Elisabetta Garibaldi; Paolo Farace; Giancarlo Lay; Gianfranco Meleddu; Pietro Gabriele
Journal:  Strahlenther Onkol       Date:  2011-07-22       Impact factor: 3.621

2.  MRI assessment of cervical cancer for adaptive radiotherapy.

Authors:  Johannes C A Dimopoulos; Gertrude Schirl; Anja Baldinger; Thomas H Helbich; Richard Pötter
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

3.  Dosimetric predictors of diarrhea during radiotherapy for prostate cancer.

Authors:  Giuseppe Sanguineti; Eugene J Endres; Maria Pia Sormani; Brent C Parker
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

4.  A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients.

Authors:  Darius Norkus; Agata Karklelyte; Benedikt Engels; Harijati Versmessen; Romas Griskevicius; Mark De Ridder; Guy Storme; Eduardas Aleknavicius; Ernestas Janulionis; Konstantinas Povilas Valuckas
Journal:  Radiat Oncol       Date:  2013-09-04       Impact factor: 3.481

5.  Long-term outcome of hypofractionated intensity-modulated radiotherapy using TomoTherapy for localized prostate cancer: A retrospective study.

Authors:  Yosuke Takakusagi; Hidemasa Kawamura; Masahiko Okamoto; Takuya Kaminuma; Nobuteru Kubo; Tatsuji Mizukami; Hiro Sato; Masahiro Onishi; Nobuaki Ohtake; Tetsuo Sekihara; Takashi Nakano
Journal:  PLoS One       Date:  2019-02-26       Impact factor: 3.240

6.  Evaluation of Safety for Scanning Carbon-Ion Radiotherapy in Hemodialysis Patients With Prostate Cancer.

Authors:  Yosuke Takakusagi; Makito Suga; Yohsuke Kusano; Kio Kano; Satoshi Shima; Keisuke Tsuchida; Nobutaka Mizoguchi; Itsuko Serizawa; Daisaku Yoshida; Tadashi Kamada; Shinichi Minohara; Hiroyuki Katoh
Journal:  Cureus       Date:  2022-02-14

7.  Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer.

Authors:  Yosuke Takakusagi; Hiroyuki Katoh; Kio Kano; Wataru Anno; Keisuke Tsuchida; Nobutaka Mizoguchi; Itsuko Serizawa; Daisaku Yoshida; Tadashi Kamada
Journal:  Radiat Oncol       Date:  2020-05-27       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.